ROHHAD is a clinical entity with a median age of 3 years at onset characterized by sudden onset of dramatic weight gain, dysautonomia, and pulmonary complications. These include alveolar hypoventilation, obstructive sleep apnea, and decreased central responsiveness to hypercarbia. There are also several endocrinopathies associated with this disorder including hypernatremia, hyperprolactinemia, hypothyroidism, hypocortisolism and diabetes insipidus. Additional features of the disease include behavioral and mood disorders, as well as seizures and learning impairment. There is an associated entity known as ROHHADNET with a predisposition towards the development of neuroectodermal tumors such as neuroblastoma and ganglioneuroma [1]. As ROHHAD could be a neurological paraneoplastic syndrome, all patients with ROHHAD syndrome should be carefully screened for the presence of these tumors [2]. There is a recent increase in the number of cases reported from Asia, and their data are included in this update.